TINA.org’s Year in Review 2024
Looking back at our accomplishments.
In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)
Looking back at our accomplishments.
How this rental car company uses subterfuge to get you to pay for something you may not need.
See how you stack up.
The new smash-hit from the Duolingo holiday album “Owl on the Prowl” 🦉
Does this company have the ammunition to support its bulletproof claims?